For biopharmaceutical companies, gene therapies are an economic challenge. They are expensive to make yet the diseases the treat are rare, so manufacturers tend to charge a lot for them to generate ...
Bionova Scientific LLC, an Asahi Kasei company and a bespoke contract development and manufacturing organization (CDMO), announced a strategic manufacturing alliance with Syenex, a genetic medicines ...
After years of delays and setbacks, the lentiviral vector gene therapy platform has secured two FDA approvals. The agency approved bluebird bio’s betibeglogene autotemcel for severe β-thalassemia in ...
Platform has the capability to reduce time from process development to GMP by 55 percent and deliver a drug product in fewer than 8 months nAAVigation platform will be launched at the Cell & Gene ...
Achieved 98% manufacturing batch success rate at BaseCamp across cell therapy, viral vector, and mRNA– Positioned U.S.-based biomanufacturing ...
Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...
This story is part of a series on the current progression in Regenerative Medicine. In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to enable in vivo gene delivery, today announced that Roche (SIX: RO, ...
Gene therapy ‘switch’ may offer non-addictive pain relief. New approach targets pain signals while leaving the rest of the brain untouched.
The gene therapy market is surging toward $36.55 billion by 2032, powered by rising demand for curative treatments that target genetic diseases at their source([1]) . The FDA approved three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback